drugset / Trial / NCT01284556

Evaluation Phenobarbital as Adjunctive Therapy in Participants With Partial Onset Seizures

NCT01284556

Phase 3 Completed 314 enrolled West-Ward Pharmaceutical
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Primary: \- to evaluate the efficacy of phenobarbital in reducing seizure frequency. Secondary: * to confirm dose response relationship, * to assess the effects on Type I seizures, * to assess the safety of phenobarbital * to assess the drug tolerability.

Timeline

Start
2010-11
Primary completion
2013-01
Completion
2016-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Phenobarbital Unknown 60 mg
Subject Phenobarbital Unknown 100 mg

Indications